Gentian Diagnostics ASA (OSL:GENT)

Market Cap	680.18M -4.9%
Revenue (ttm)	176.50M +16.1%
Net Income	13.26M -70.7%
EPS	0.86 -70.1%
Shares Out	15.46M
PE Ratio	51.19
Forward PE	16.79
Dividend	0.60 (1.36%)
Ex-Dividend Date	May 6, 2026

Volume	3,713
Average Volume	11,546
Open	43.80
Previous Close	44.10
Day's Range	43.60 - 44.00
52-Week Range	36.10 - 65.80
Beta	0.32
RSI	60.08
Earnings Date	May 6, 2026

About Gentian Diagnostics ASA

Gentian Diagnostics ASA develops, manufactures, and sells biochemical reagents for use in medical diagnostics and research in the United States, Asia, and Europe. It offers in-vitro diagnostic reagents for clinical chemistry analyzers, such as Gentian Calprotectin Immunoassay, a turbidimetric assay used for the measurement of circulating calprotectin in plasma and serum for detection and assessment of inflammation; Gentian Cystatin C Immunoassay test kit, a GFR marker for the diagnosis and therapeutic control of renal function and chronic kidne...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2001
• Employees: 64
• Stock Exchange: Oslo Børs
• Ticker Symbol: GENT

Financial Performance

In 2025, Gentian Diagnostics ASA's revenue was 176.50 million, an increase of 16.07% compared to the previous year's 152.07 million. Earnings were 13.26 million, a decrease of -70.73%.